Dystonic Crisis

Disclaimer: This information is intended for educational purposes and as a general reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made based on individual patient circumstances, current clinical guidelines, and the judgment of a qualified healthcare provider. This resource does not endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned herein. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. In case of a medical emergency, call 911 immediately.

Overview

• Definition: A dystonic crisis, also known as status dystonicus or dystonic storm, is a rare but life-threatening neurological emergency characterized by rapidly escalating, severe, generalized dystonia that leads to continuous or frequently recurring sustained involuntary muscle contractions. These contractions can result in rhabdomyolysis, hyperthermia, metabolic acidosis, renal failure, and respiratory compromise, potentially leading to multi-organ failure and death if not promptly recognized and treated.
• Epidemiology: Dystonic crisis is rare. Its exact incidence is unknown. It is most commonly seen in patients with pre-existing primary (genetic) or secondary dystonia, particularly those with mutations in DYT-TOR1A (formerly DYT1), ATP1A3 (rapid-onset dystonia-parkinsonism), or metabolic disorders. Drug-induced acute dystonic reactions are more common, but progression to a generalized dystonic crisis is less frequent, though possible, especially with high-potency dopamine receptor blocking agents (e.g., typical antipsychotics, metoclopramide) or rapid withdrawal of anti-dystonic medications (e.g., levodopa in Parkinson's disease). It can affect all age groups but is more frequently described in children and young adults with genetic dystonias.
• Classification:
  • Primary Dystonic Crisis: Occurs in individuals with genetic or idiopathic primary dystonia, often triggered by stress, infection, surgery, or medication changes.
  • Secondary Dystonic Crisis:
    • Drug-induced: Most commonly due to dopamine receptor blockers (antipsychotics, antiemetics), but also can be caused by illicit drugs, antiepileptics, or withdrawal from certain medications (e.g., baclofen, levodopa).
    • Metabolic: Associated with inherited metabolic disorders (e.g., glutaric aciduria type 1, methylmalonic acidemia, mitochondrial disorders, Wilson's disease).
    • Structural Lesions: Less common, but can occur with basal ganglia lesions (e.g., stroke, tumor, infection).
    • Autoimmune/Inflammatory: Rare, e.g., anti-NMDA receptor encephalitis.

Pathophysiology

• Mechanism: The exact mechanism of dystonic crisis is not fully understood but involves severe dysfunction within the basal ganglia-thalamocortical motor circuit, leading to disordered motor control.
  • Dopaminergic Dysregulation: In drug-induced cases, acute blockade of postsynaptic D2 dopamine receptors in the basal ganglia by medications like antipsychotics or metoclopramide leads to an imbalance between dopamine and acetylcholine, resulting in excessive cholinergic activity and dystonic movements. Withdrawal of dopaminergic medications can also precipitate a crisis.
  • Neurotransmitter Imbalance: Imbalances in other neurotransmitters (e.g., GABA, glutamate, serotonin) are also implicated, particularly in genetic forms.
  • Basal Ganglia Dysfunction: Structural or functional abnormalities in the putamen, globus pallidus, and substantia nigra contribute to the sustained muscle contractions.
  • Energy Depletion: Sustained muscle contractions lead to massive energy expenditure, resulting in lactic acidosis, hyperthermia, and rhabdomyolysis.
• Risk Factors:
  • Pre-existing Dystonia: Patients with known primary or secondary dystonia, especially genetic forms (e.g., DYT-TOR1A).
  • Medication Exposure:
    • Dopamine receptor blocking agents (DRBAs): Typical antipsychotics (haloperidol, fluphenazine), atypical antipsychotics (less common, but possible with risperidone, olanzapine), antiemetics (metoclopramide, prochlorperazine).
    • Anticholinergic withdrawal.
    • Levodopa withdrawal/"off" states in Parkinson's disease.
    • Rapid withdrawal of intrathecal baclofen.
  • Intercurrent Illness: Infections (especially fever), dehydration, electrolyte disturbances, metabolic derangements.
  • Stressors: Surgery, general anesthesia, psychological stress, sleep deprivation.
  • Trauma: Head injury.
  • Genetic Predisposition: Specific gene mutations (DYT-TOR1A, ATP1A3, etc.).
  • Young Age: Children and young adults with genetic dystonias are more susceptible.
• Protective Factors:
  • Optimal management of chronic dystonia with stable medication regimens.
  • Avoidance of known precipitants (e.g., DRBAs in susceptible individuals).
  • Careful medication titration and withdrawal.
  • Prompt treatment of intercurrent illnesses.
  • Genetic counseling for at-risk families.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Rapid escalation of sustained, involuntary, often painful muscle contractions.
  • Abnormal, fixed or fluctuating postures involving the trunk, limbs, neck (torticollis, retrocollis, anterocollis), and face (blepharospasm, oromandibular dystonia).
  • Opisthotonus (severe arching of the back).
  • Severe generalized muscle spasms, often twisting and repetitive.
  • Pain: Extreme, due to muscle overactivity.
  • Dysarthria and dysphagia: Due to involvement of oromandibular and laryngeal muscles.
  • Agitation and anxiety (often secondary to pain and distress).
• Early Signs:
  • Increasing frequency or severity of pre-existing dystonic movements.
  • New onset focal dystonia rapidly spreading to generalized dystonia.
  • Restlessness, inability to find a comfortable position.
  • Difficulty speaking or swallowing.
  • Mild tachycardia or tachypnea.
• Advanced Signs:
  • Respiratory distress or failure: Due to laryngeal dystonia (laryngospasm), pharyngeal dystonia, diaphragmatic spasms, or severe truncal dystonia impairing ventilation.
  • Hyperthermia: Due to excessive muscle activity, can be >40°C.
  • Rhabdomyolysis: Severe muscle breakdown, leading to muscle tenderness, weakness, and dark urine.
  • Metabolic acidosis: Due to lactic acid accumulation.
  • Acute kidney injury: Secondary to rhabdomyolysis (myoglobinuria).
  • Cardiac arrhythmias: Due to electrolyte imbalances.
  • Altered mental status, obtundation, or coma.
  • Autonomic instability: Tachycardia, labile blood pressure, sweating.
• Atypical Presentations:
  • May present primarily with autonomic symptoms or altered consciousness in some metabolic disorders.
  • Focal dystonia that rapidly generalizes without clear preceding signs.
  • Mild forms sometimes mistaken for severe anxiety or pain.

Physical Examination

• Inspection:
  • Observe severe, sustained muscle contractions causing grotesque, contorted postures of the trunk, limbs, neck, and face.
  • Evidence of drooling, difficulty handling secretions.
  • Signs of respiratory distress: accessory muscle use, retractions, paradoxical breathing.
  • Diaphoresis (excessive sweating).
  • Dark, tea-colored urine (suggesting rhabdomyolysis).
  • Evidence of recent trauma from uncontrolled movements (e.g., bruising).
• Palpation:
  • Extremely tense, firm, painful muscles.
  • Warm skin due to hyperthermia.
  • Assess for bladder distention.
• Special Tests:
  • Airway assessment: Crucial to determine patency and need for intubation.
  • Neurological examination: May be difficult due to severe dystonia. Assess level of consciousness, cranial nerves (if possible), and motor strength after muscle relaxation.
  • Vitals: Frequent monitoring of temperature, heart rate, respiratory rate, blood pressure, and oxygen saturation.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Progression: When did symptoms begin? How rapidly did they progress?
  • Preceding Events: Any recent infections, fever, trauma, surgery, or psychological stress?
  • Medication History:
    • Recent initiation or dose changes of any medications, especially antipsychotics, antiemetics, or dopaminergic drugs.
    • Withdrawal from any chronic medications (e.g., baclofen pump failure/withdrawal, levodopa).
    • Use of illicit drugs.
  • Past Medical History:
    • Known diagnosis of dystonia (primary or secondary)?
    • Other neurological conditions?
    • Metabolic disorders?
    • Psychiatric history (relevant for drug-induced cases)?
  • Family History: Any family members with dystonia, movement disorders, or unexplained neurological conditions?
  • Associated Symptoms: Fever, weakness, dark urine, difficulty breathing, swallowing, pain.
• Red Flags:
  • Rapidly worsening generalized dystonia.
  • Signs of respiratory distress (dyspnea, stridor, cyanosis).
  • Hyperthermia (>38.5°C).
  • Signs of rhabdomyolysis (muscle pain, tenderness, dark urine).
  • Altered mental status.
  • Autonomic instability.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): To assess for infection (leukocytosis) or baseline status.
  • Electrolytes: Na, K, Cl, HCO3 (to assess for metabolic acidosis), Ca, Mg, Phos.
  • Renal Function Tests: BUN, Creatinine (to assess for acute kidney injury secondary to rhabdomyolysis).
  • Liver Function Tests (LFTs): Baseline and for assessment of potential drug-induced injury or underlying metabolic conditions (e.g., Wilson's disease).
  • Creatine Kinase (CK): Crucial for diagnosing and monitoring rhabdomyolysis. Levels can be extremely high (>10,000 U/L).
  • Arterial Blood Gas (ABG): To assess for metabolic acidosis and respiratory compromise.
  • Urinalysis: To check for myoglobinuria.
  • Toxicology Screen (Urine/Blood): If drug-induced dystonia is suspected, including recreational drugs.
  • Serum Ceruloplasmin and Urine Copper: If Wilson's disease is suspected, especially in younger patients with unexplained dystonia.
• Confirmatory (for underlying cause, if not clear from first-line):
  • Genetic Testing: For primary dystonias (DYT-TOR1A, ATP1A3, etc.) if history suggests inherited form.
  • Metabolic Workup: Ammonia, lactate, pyruvate, amino acids, urine organic acids if metabolic disorder is suspected (especially in children with no clear etiology).
• Monitoring:
  • Serial CK levels (daily or more frequently depending on values).
  • Serial electrolytes and renal function.
  • Repeat ABGs.

Imaging

• Recommended:
  • Brain MRI: Usually normal in primary dystonias but important to rule out structural brain lesions (stroke, tumor, encephalitis, basal ganglia calcifications) or specific metabolic disorders (e.g., glutaric aciduria type 1). May show signal abnormalities in basal ganglia in some secondary dystonias.
• Advanced:
  • CT scan of the head: May be used as a rapid initial screen for acute structural lesions in an emergency setting if MRI is not immediately available or contraindicated.
  • Cardiac imaging (ECG, ECHO): If cardiac arrhythmias or cardiomyopathy are suspected complications.

Management

Dystonic crisis is a medical emergency requiring prompt recognition and aggressive supportive care in an intensive care setting.

Acute Management

• Immediate (within the first hour):
  1. Airway, Breathing, Circulation (ABC):
     • Assess airway patency. Be prepared for urgent intubation and mechanical ventilation if there is any sign of respiratory compromise (laryngospasm, hypoventilation, severe truncal dystonia affecting breathing). Supraglottic airway devices are often difficult to place due to muscle rigidity.
     • Administer supplemental oxygen.
     • Establish intravenous access (at least two large-bore IVs).
     • Monitor vital signs continuously (HR, BP, RR, SpO2, core temperature).
  2. Pharmacological Intervention (First-line):
     • Benzodiazepines: Potentiate GABAergic inhibition, providing immediate muscle relaxation.
       • Lorazepam: 1-2 mg IV every 5-15 minutes until dystonia improves or sedation is achieved. Max 10 mg/hour.
       • Diazepam: 5-10 mg IV slowly, repeat every 10-15 minutes as needed.
       • Note: High doses may be required. Be prepared for sedation and respiratory depression.
     • Anticholinergics: Block muscarinic acetylcholine receptors, effective for drug-induced dystonia.
       • Benztropine: 1-2 mg IV slowly, may repeat once after 20-30 minutes if needed.
       • Diphenhydramine: 25-50 mg IV slowly, may repeat once after 20-30 minutes if needed (antihistamine with anticholinergic properties).
       • These are particularly effective for acute drug-induced dystonia.
• Stabilization (Early management priorities):
  1. Identify and remove/reverse the precipitating factor:
     • Discontinue offending drugs (e.g., antipsychotics, antiemetics).
     • Restart or increase dose of previously withdrawn anti-dystonic medications (e.g., levodopa, baclofen).
     • Treat infection, fever, metabolic derangements.
  2. Hydration: Aggressive IV fluid administration (e.g., normal saline) to prevent and treat acute kidney injury from rhabdomyolysis. Maintain urine output >2-3 mL/kg/hr.
  3. Temperature Control: Active cooling measures if hyperthermia develops (cooling blankets, ice packs, antipyretics are generally ineffective for hyperthermia due to muscle activity).
  4. Electrolyte Correction: Correct hyperkalemia, hyperphosphatemia, hypocalcemia secondary to rhabdomyolysis.
  5. Pain Management: Opioids may be needed for severe pain, but careful titration due to respiratory depression risk, especially when combined with benzodiazepines.
• Emergency (Crisis management if refractory):
  1. Continuous IV infusions:
     • Midazolam infusion: If bolus benzodiazepines are insufficient (e.g., 0.05-0.2 mg/kg/hr).
     • Propofol infusion: For deep sedation and muscle relaxation, especially if intubated (e.g., 5-50 mcg/kg/min).
  2. Neuromuscular Blocking Agents (NMBAs): If severe, life-threatening dystonia persists and compromises ventilation despite maximal sedation.
     • Rocuronium, Vecuronium: For ongoing paralysis while intubated.
     • Succinylcholine: Can be used for rapid sequence intubation, but caution in rhabdomyolysis due to risk of hyperkalemia.
     • Note: NMBAs only paralyze the muscles; they do not treat the underlying central nervous system dysfunction. The patient remains conscious and in pain unless adequately sedated.
  3. Specific Interventions for refractory cases:
     • Deep Brain Stimulation (DBS): In patients with established DBS for dystonia, increasing stimulation parameters or optimizing programming can be life-saving. For patients without DBS, urgent implantation may be considered in specialized centers for extreme refractory cases.
     • Intrathecal Baclofen: If already on an ITB pump, check pump function. For severe primary or secondary dystonia unresponsive to IV medications, intrathecal baclofen may be considered.
     • Surgical Interventions: Pallidotomy or other ablative procedures are rarely considered in acute crisis but may be a desperate measure for extreme refractory cases or if DBS is not feasible.

Chronic Management

Once the acute crisis is resolved, focus shifts to preventing recurrence and managing the underlying dystonia. - Pharmacological: * Anticholinergics (Oral): Trihexyphenidyl (Artane), benztropine (Cogentin) are mainstay for many forms of dystonia, particularly primary and drug-induced. Titrate dose slowly to effect. * Benzodiazepines (Oral): Clonazepam, diazepam may be used for ongoing muscle relaxation, but long-term use is limited by tolerance and side effects. * Baclofen (Oral): Useful for generalized dystonia, especially spinal forms. * Tetrabenazine/Deutetrabenazine: Dopamine-depleting agents, useful for tardive dystonia or certain hyperkinetic movement disorders. * Botulinum Toxin Injections: For focal dystonia, but generally not used for generalized crisis management due to diffuse nature. May be part of long-term management for specific muscle groups. * Specific therapies for metabolic disorders: e.g., copper chelators for Wilson's disease. - Non-pharmacological: * Physical Therapy: To prevent contractures, maintain range of motion, and manage pain. * Occupational Therapy: To improve functional independence. * Speech Therapy: For dysarthria and dysphagia. * Psychological Support: For coping with chronic illness and anxiety. * Avoidance of Triggers: Education on medication adherence, avoiding precipitating drugs, managing stress, and promptly treating infections. - Monitoring: * Regular follow-up with a movement disorder specialist. * Monitoring of medication efficacy and side effects. * Regular assessment for early signs of dystonia exacerbation. * For patients with DBS, routine programming adjustments. * For patients on ITB, regular pump refills and function checks.

Treatment Algorithms

• First-Line (Acute):
  1. ABC stabilization, continuous monitoring.
  2. IV Lorazepam (1-2 mg q5-15 min) AND IV Benztropine (1-2 mg) or Diphenhydramine (25-50 mg).
  3. Fluid resuscitation for rhabdomyolysis and hyperthermia control.
• Second-Line (Refractory to first-line):
  1. Consider continuous IV Midazolam or Propofol infusion.
  2. Consult anesthesiology for intubation and mechanical ventilation if not already done.
  3. If drug-induced, consider dantrolene (250 mg IV initial bolus, then 1 mg/kg every 6 hours if NMS-like features present, up to 10 mg/kg total) if hyperthermia and rigidity are prominent.
• Refractory Cases (Life-threatening, unresponsive to conservative measures):
  1. Consider neuromuscualr blockade (e.g., Vecuronium, Rocuronium) with ongoing deep sedation (propofol) if intubated.
  2. Neurology/Movement Disorder Specialist consultation for consideration of:
     • Urgent Deep Brain Stimulation (DBS) adjustment/implantation.
     • Intrathecal Baclofen administration (if appropriate).
     • ECT (Electroconvulsive Therapy) has been reported in very rare, extreme cases.

Complications

• Common:
  • Pain
  • Dehydration
  • Muscle fatigue
  • Anxiety/agitation
• Serious:
  • Respiratory Failure: Due to laryngospasm, pharyngeal muscle involvement, or severe truncal/diaphragmatic dystonia. This is the most common cause of death.
  • Rhabdomyolysis: Leads to acute kidney injury, hyperkalemia, hyperphosphatemia, hypocalcemia, metabolic acidosis.
  • Hyperthermia: Due to intense muscle activity, can lead to multi-organ failure.
  • Metabolic Acidosis: Lactic acidosis from muscle overactivity.
  • Aspiration Pneumonia: Due to dysphagia and inability to protect airway.
  • Peripheral Nerve Injury/Compartment Syndrome: Rare, due to sustained muscle contraction.
  • Fractures/Dislocations: Rarely, due to violent contractions.
• Long-term:
  • Persistent contractures and deformities if not adequately managed.
  • Chronic pain.
  • Functional disability.
  • Psychological sequelae (PTSD, depression, anxiety).
  • Recurrence of dystonic crisis if underlying cause not addressed or prophylaxis is inadequate.

Prognosis

• Factors:
  • Underlying cause: Drug-induced dystonic crisis generally has an excellent prognosis if recognized early and treated promptly. Genetic/metabolic forms may have a more guarded prognosis, especially if there is significant baseline neurological impairment.
  • Timeliness of treatment: Prompt diagnosis and aggressive management significantly improve outcomes. Delayed treatment increases the risk of complications.
  • Severity of complications: Development of rhabdomyolysis, severe hyperthermia, or respiratory failure worsens prognosis.
  • Access to specialized care: Management in an ICU setting with neurologists experienced in movement disorders improves outcomes.
• Survival: Mortality rates are difficult to quantify due to rarity but can be as high as 10-20% if not promptly and aggressively treated, primarily due to respiratory failure and multi-organ dysfunction from rhabdomyolysis/hyperthermia.
• Quality of Life: Patients who survive a dystonic crisis may experience long-term functional deficits, chronic pain, and psychological distress, particularly if the underlying dystonia remains poorly controlled or if severe complications occurred.

Prevention

• Primary: Preventing initial occurrence.
  • Judicious use of DRBAs: Avoid or use with extreme caution in patients with a history of dystonia or those with risk factors (e.g., young males). If DRBAs are necessary, consider concomitant anticholinergic prophylaxis, especially during initiation or dose escalation.
  • Genetic Counseling: For families with inherited dystonia.
  • Early Diagnosis and Treatment: Of underlying metabolic disorders.
• Secondary: Early detection and intervention.
  • Patient Education: Educate patients with dystonia and their caregivers about early signs of worsening dystonia or crisis, and the importance of prompt medical attention.
  • Medication Adherence: Emphasize strict adherence to anti-dystonic medication regimens.
  • Careful Medication Management: Slow and gradual titration/withdrawal of medications that can precipitate dystonia (e.g., levodopa, baclofen).
  • Prophylaxis: In high-risk situations (e.g., surgery, acute illness), consider prophylactic benzodiazepines or anticholinergics for patients with established dystonia.
• Tertiary: Preventing complications.
  • Aggressive Supportive Care: If a crisis occurs, prompt management as outlined in the "Acute Management" section is crucial to prevent life-threatening complications.
  • Long-term management of dystonia: Optimize chronic treatment (oral medications, botulinum toxin, DBS, ITB) to reduce the risk of future crises.

Special Populations

• Pediatric:
  • More common in children with inherited dystonias (e.g., DYT-TOR1A, ATP1A3).
  • Metabolic disorders (e.g., glutaric aciduria type 1) are important considerations.
  • Drug dosing requires weight-based calculations.
  • Early recognition can be challenging as children may not verbalize symptoms clearly.
  • Higher risk of rhabdomyolysis and related complications due to higher metabolic rate.
• Geriatric:
  • Less common, but drug-induced dystonia can occur with lower doses of DRBAs due to altered pharmacokinetics/dynamics.
  • Increased susceptibility to adverse effects of anticholinergics (confusion, urinary retention).
  • Increased risk of complications due to comorbidities.
• Pregnancy:
  • Management is challenging due to potential teratogenicity of medications.
  • Benzodiazepines (e.g., lorazepam) are Category D (risk in first trimester), but benefit may outweigh risk in life-threatening emergency.
  • Anticholinergics (e.g., benztropine) are Category C.
  • Consult with an obstetrician and neurologist is crucial.
• Comorbidities:
  • Renal Impairment: Dose adjustments needed for renally excreted medications (e.g., baclofen, some benzodiazepines). Increased risk of acute kidney injury from rhabdomyolysis.
  • Hepatic Impairment: Dose adjustments for hepatically metabolized medications.
  • Psychiatric Illness: Common in patients on antipsychotics. Need to balance treatment of psychosis with avoiding dystonia.
  • Parkinson's Disease: Dystonic crisis can occur during "off" periods or levodopa withdrawal.

Clinical Pearls

• Diagnostic:
  • Think Dystonic Crisis in any patient with acute, severe, unexplained generalized muscle contractions, especially if on dopamine receptor blockers or with a history of dystonia.
  • Don't mistake severe agitation or psychosis for dystonia: Administering more antipsychotics can worsen drug-induced dystonia.
  • Laryngospasm is a critical red flag: It can lead to rapid respiratory arrest.
  • CK level is mandatory: Even if there are no overt signs of rhabdomyolysis, the massive muscle activity will elevate CK.
• Treatment:
  • "Bend, then Lend": BEND (Benzodiazepines) are generally first-line for acute control, then LEND (anticholinergics like benztropine or diphenhydramine) are useful, especially for drug-induced cases.
  • Airway is paramount: Always prioritize airway management. Do not delay intubation if airway compromise or respiratory failure is imminent.
  • High doses may be needed: Patients in dystonic crisis often require significantly higher doses of benzodiazepines and anticholinergics than typically used.
  • NMBAs are for ventilation, not treatment: Paralytics only mask the dystonia; they do not address the underlying CNS pathology. Continue deep sedation alongside NMBAs.
  • Consider specific antidotes: E.g., restart baclofen if intrathecal pump failure, or levodopa for Parkinsonian dystonia.
• Pitfalls:
  • Delayed diagnosis: Due to rarity or misdiagnosis as agitation, tetanus, or seizures.
  • Under-dosing of medications: Leading to inadequate control and worsening crisis.
  • Failure to remove offending agent: Or to restart necessary medications.
  • Ignoring complications: Not monitoring for rhabdomyolysis, AKI, hyperthermia.
  • Premature cessation of treatment: Dystonia can recur if medications are stopped too early.

Recent Updates

• Guidelines: Consensus guidelines emphasize early recognition, aggressive supportive care, and sequential pharmacotherapy (benzodiazepines, anticholinergics, continuous sedation, and NMBAs if necessary). Recommendations for the role of DBS in refractory cases are strengthening, with consideration for urgent implantation in life-threatening situations in specialized centers.
• Evidence: Increasing evidence supports the efficacy of rapid and high-dose benzodiazepine and anticholinergic administration for acute control. Research continues into the genetic underpinnings of dystonia, which may lead to more targeted therapies and better risk stratification. The role of continuous infusions of sedatives (midazolam, propofol) is well-established for managing the acute phase.
• Controversies: Optimal long-term management strategies for preventing recurrence in certain rare forms of dystonia. The exact timing and indications for emergent DBS implantation in refractory crisis are still areas of ongoing discussion among experts.

Key References

• Guidelines:
  • Movement Disorder Society (MDS) consensus statements on dystonia management.
  • Critical care guidelines for management of acute neurological emergencies.
• Studies:
  • Major clinical trials and observational studies on the efficacy of benzodiazepines, anticholinergics, and DBS in dystonia.
  • Genetic studies identifying novel dystonia genes and their clinical correlates.
• Reviews:
  • Comprehensive review articles on status dystonicus/dystonic crisis in neurology and movement disorders journals.
  • Review articles on drug-induced movement disorders.